METTL3 and triple-negative breast carcinoma: In addition, the low expression of METTL3, an important m6A writer, was found to be correlated with the poor prognosis of triple-negative breast cancer (TNBC), and METTL3 might serve as a novel therapeutic target in TNBC metastasis (Shi et al., 2020).